PHARMACEUTICAL, CONTAINING EPITOPE PEPTIDES HIG2 AND URLC10, FOR CANCER TREATMENT, METHODS AND MEANS FOR INDUCTION OF ANTIGEN-PRESENTING CELL AND CYTOTOXIC T-LYMPHOCYTE (CTL), ANTIGEN-PRESENTING CELL AND CTL, OBTAINED THEREOF, METHOD AND MEANS OF IMMUNE ANTI-CANCER RESPONSE Russian patent published in 2014 - IPC A61K38/04 A61P35/00 C07K9/00 C12N5/783 C12N5/784 

FIELD: medicine, pharmaceutics.

SUBSTANCE: presented solutions relate to field of immunology. Claimed are: pharmaceutical, containing peptide, obtained from HIG2 or URLC10, capable of inducing cytotoxic T-lymphocytes (CTL) by formation of antigen-presenting complex with antigen HLA-A0206. Described are isolated antigen-presenting cell and CTL and methods for their induction. Antigen-presenting cell is induced by contact of cell, expressing antigen HLA-A0206, with peptide, obtained from HIG2 or URLC10. Cytotoxic lymphocyte is induced by contact of CD8-positive T-cell with antigen-presenting cell, presenting on its surface complex of antigen HLA-A0206 and peptide, obtained from HIG2 or URLC10. Characterised are method and means of immune anti-tumour response induction by introduction to patient of medication, which contains peptide, capable of inducing CTL.

EFFECT: claimed inventions can be used in treatment of cancer disease, characterised by higher expression of HIG2 or URLC10.

12 cl, 8 dwg